Off

Renal Medicine Research

Our Renal Research Unit continues to have an active and expanding program of clinical research. With fourteen active trials, the main theme of our program is involvement in studies designed to improve the outcomes for people with kidney disease. Our program includes studies initiated by investigators, collaborative groups and pharmaceutical clinical trials investigating the progression and complications of chronic kidney disease.

Selected Grants

Amount awarded	Grant and project details
$5,736,696	NHMRC Clinical Trials and Cohort Studies, 2023-2027 Oral fenofibrate therapy to retard Chronic Kidney Disease in Type 2 diabetes. Investigator: Jardine M (CIC).
$4,057,466	NHMRC Clinical Trials and Cohort Studies, 2023-2027 Dexmedetomidine in Cardiac surgical Intraoperative Drug Evaluation (DECIDE). Investigator: Jardine M (CIB).
$3,257,170	NHMRC Investigator Grants, 2023-2027 Leadership 2: Addressing unmet needs in chronic disease through innovations in trial design and delivery. Investigator: Jardine M.
$1,954,074	NHMRC Investigator Grants, 2022-2025 Transforming Outcomes for Pulmonary Fibrosis. Investigator: Jardine M (CIA).
$5,000,000	NHMRC Synergy Grant, 2021-2025 Defining the role and therapeutic manipulation of the gut-lung axis in respiratory disease. Investigator: Jardine M (CID).
$4,353,258	NHMRC CTCS Project Grant, 2020-2024 Evaluation of the efficacy and safety of health service dialysate sodium practice on clinical outcomes. Investigator: Jardine M (CIA).
$5,522,418	NHMRC Project Grant, 2019-2024 Treatment of cardiovascular disease with very low dose Rivaroxaban in Advanced Chronic Kidney disease (The TRACK Trial). Investigator: Jardine M (CIC).

Our Publications

2024

Cheung CK, Barratt J, Carroll K, Lafayette RA, Liew A, Suzuki Y, Tesař V, Trimarchi H, Wong MG, Zhang H, Perkovic V, Rizk DV. Targeting APRIL in the Treatment of IgA Nephropathy. Clin J Am Soc Nephrol. 2024 Mar 1;19(3):394-398. doi: 10.2215/CJN.0000000000000338. Epub 2023 Oct 6.

Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, Sahay M, Suzuki Y, Wong MG, Yarbrough J, Xia J, Pereira BJG; ENVISION Trial Investigators Group. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. N Engl J Med. 2024 Jan 4;390(1):20-31. doi: 10.1056/NEJMoa2305635. Epub 2023 Nov 2.

Sun J, Wong MG. Haematuria in immunoglobulin a nephropathy: To be or not to be? Nephrology (Carlton). 2024 Feb;29(2):63-64. doi: 10.1111/nep.14272. Epub 2024 Jan 17.

Vaara ST, Serpa Neto A, Bellomo R, Adhikari NKJ, Dreyfuss D, Gallagher M, Gaudry S, Hoste E, Joannidis M, Pettilä V, Wang AY, Kashani K, Wald R, Bagshaw SM, Ostermann M; STandard vs. Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) Investigators. Regional Practice Variation and Outcomes in the Standard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) Trial: A Post Hoc Secondary Analysis. Crit Care Explor. 2024 Feb 19;6(2):e1053. doi: 10.1097/CCE.0000000000001053.

Francis A, Wainstein M, Irish G, Abdul Hafidz MI, Chen T, Cho Y, Htay H, Kanjanabuch T, Lalji R, Neuen BL, See E, Shah A, Smyth B, Tungsanga S, Viecelli A, Yeung EK, Arruebo S, Bello AK, Caskey FJ, Damster S, Donner JA, Jha V, Johnson DW, Levin A, Malik C, Nangaku M, Okpechi IG, Tonelli M, Ye F, Wong MG, Bavanandan S; Regional Board and ISN-GKHA Team Authors. Capacity for the management of kidney failure in the International Society of Nephrology Oceania and South East Asia (OSEA) region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA). Kidney Int Suppl (2011). 2024 Apr;13(1):110-122. doi: 10.1016/j.kisu.2024.01.004. Epub 2024 Apr 8.

Trachtman H, Radhakrishnan J, Rheault MN, Alpers CE, Barratt J, Heerspink HJL, Noronha IL, Perkovic V, Rovin B, Trimarchi H, Wong MG, Mercer A, Inrig J, Rote W, Murphy E, Bedard PW, Roth S, Bieler S, Komers R. Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study. Kidney Int Rep. 2024 Jan 28;9(4):1020-1030. doi: 10.1016/j.ekir.2024.01.032.

Trần TB, Ambrens M, Nguyễn J, Coleman E, Gilanyi Y, Letton M, Pandit A, Lock L, Thom JM, Sen S, Lambert K, Arnold R. Preferences of people with chronic kidney disease regarding digital health interventions that promote healthy lifestyle: qualitative systematic review with meta-ethnography. BMJ Open. 2024 May 27;14(5):e082345. doi: 10.1136/bmjopen-2023-082345.

Letton ME, Trần TB, Flower S, Wewege MA, Wang AY, Sandler CX, Sen S, Arnold R. Digital Physical Activity and Exercise Interventions for People Living with Chronic Kidney Disease: A Systematic Review of Health Outcomes and Feasibility. J Med Syst. 2024 Jul 1;48(1):63. doi: 10.1007/s10916-024-02081-z.

Wang AY, Serpa Neto A, Gallagher M, Wald R, Bagshaw SM, Bellomo R; STARRT-AKI Investigators. Association of Age, Frailty, and Strategy for Initiation of Renal-Replacement Therapy: A Post Hoc analysis of the STARRT-Acute Kidney Injury Trial. Blood Purif. 2024;53(10):781-792. doi: 10.1159/000540323. Epub 2024 Jul 24.

Kim D, Lv J, Hladunewich M, Jha V, Hooi LS, Monaghan H, Shan S, Reich HN, Barbour S, Billot L, Zhang H, Perkovic V, Wong MG; TESTING trial steering committee. The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy. Kidney Int Rep. 2024 Apr 3;9(7):2168-2179. doi: 10.1016/j.ekir.2024.03.032.

Cooper M, Cherney DZI, Greene TH, Heerspink HJL, Jardine M, Lewis JB, Wong MG, Baquero E, Heise M, Jochems J, Lanchoney D, Liss C, Reiser D, Scotney P, Velkoska E, Dwyer JP. Vascular Endothelial Growth Factor-B Blockade with CSL346 in Diabetic Kidney Disease: A Phase 2A Randomized Controlled Trial. J Am Soc Nephrol. 2024 Nov 1;35(11):1546-1557. doi: 10.1681/ASN.0000000000000438. Epub 2024 Aug 16.

Cheung CK, Barratt J, Lafayette R, Liew A, Suzuki Y, Tesař V, Trimarchi H, Wong MG, Zhang H, Rizk DV. Targeting APRIL in the treatment of glomerular diseases. Kidney Int. 2024 Nov;106(5):806-818. doi: 10.1016/j.kint.2024.08.012. Epub 2024 Sep 7.

Hunter-Dickson M, Wong MG. The role of endothelin receptor antagonists in IgA nephropathy. Nephrology (Carlton). 2024 Sep;29 Suppl 2:30-33. doi: 10.1111/nep.14364.

Li J, Lv J, Wong MG, Shi S, Zan J, Monaghan H, Perkovic V, Zhang H; TESTING Study Biomarker Group. Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy. Kidney Int Rep. 2024 Aug 3;9(10):3016-3026. doi: 10.1016/j.ekir.2024.07.031.

Li PK, Ng JK, Cai GY, Chen W, Chow KM, Fan S, He JC, Hooi LS, Pei Y, Teo BW, Wong MG, Wu IW, Zhou J, Tian N, Ye Z, Yu X. Navigating the Global Economic Landscape of Dialysis: A Summary of Expert Opinions from The 4th International Congress of Chinese Nephrologists. Kidney Dis (Basel). 2024 Jul 24;10(5):384-397. doi: 10.1159/000540152.

Hunter-Dickson M, Sen S. Audit of haemodialysis adequacy to provide more personalised and green nephrology care. Nephrology. 2024;29:65.

Khanna R, Chandra A, Sen S, Konyukhov Y, Fuentes E, Burmistrov I, Kravchenko M. Microplastics and nanoplastics as environmental contaminants of emerging concern: Potential hazards for human health. Sustainability. 2024;16(19):8704.

Theivendran T, Sen S. Development of criteria led discharge for uncomplicated kidney and urinary tract infections: A quality assurance study of admissions at Concord Hospital over a 12-month period. Nephrology. 2024;29:85–86.

Tran TB, Tahir NUE, Bates A, Nguyễn J, Cheikh Hassan HI, Sen S, Lambert K, Arnold R. Physical activity recommendations for people with chronic kidney disease: Are research participants representative of real-world patients? J Clin Exerc Physiol. 2024;13(s2):424.

Van KL, Chong J, Tienstra L, Konda M, Van der Linde R, Chen V, Sen S, Lambert K, Arnold R. Impact of prophylactic-dose enoxaparin anticoagulation on anti-Xa levels, bleeding and extracorporeal circuit thrombosis in patients on chronic intermittent haemodialysis. Nephrology. 2024;29:102–103.

Wang AY, Ngo J, Perera PS, Higgins K, Eyles N, Endre Z, Sen S, Wong MG, Wynter LA, Killen JP, Bompoint S. ePidEmiology, Risk FactORs, and outcoMes of AKI (PERFORM-AKI): FR-PO034. J Am Soc Nephrol. 2024;35(10 Suppl):10–1681.

2023

Barratt J, Rovin B, Wong MG, Alpers CE, Bieler S, He P, Inrig J, Komers R, Heerspink HJL, Mercer A, Noronha IL, Radhakrishnan J, Rheault MN, Rote W, Trachtman H, Trimarchi H, Perkovic V; PROTECT investigators. IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study. Kidney Int Rep. 2023 Mar 4;8(5):1043-1056. doi: 10.1016/j.ekir.2023.02.1086.

Chandra Y, Malani J, Irvine JH, Krishnan A, Johnson DW, Ritchie AG, Palmer SC. Incidence, treatment patterns and clinical outcomes associated with acute kidney injury in Fiji: a retrospective cohort study. J Nephrol. 2023 Jul;36(6):1689-1692. doi: 10.1007/s40620-023-01628-6. Epub 2023 Apr 24.

Charytan DM, Mahaffey KW, Jardine MJ, Cannon CP, Neal B, Lambers Heerspink HJ, Agarwal R, Bakris GL, de Zeeuw D, Levin A, Pollock C, Zhang H, Zinman B, Rosenthal N, Perkovic V, Di Tanna GL, Yu J, Rogers K, Arnott C, Wheeler DC. Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering. BMJ Open Diabetes Res Care. 2023 Jun;11(3):e003270. doi: 10.1136/bmjdrc-2022-003270.

Collister D, Pyne L, Bhasin AA, Ahmed SB, Smyth B, Herrington W, Jardine M, Walsh M. Sex and Gender in Randomized Controlled Trials of Adults Receiving Maintenance Dialysis: A Meta-epidemiologic Study. Am J Kidney Dis. 2023 May;81(5):575-582.e1. doi: 10.1053/j.ajkd.2022.10.015. Epub 2022 Dec 16.

Eckardt KU, Delgado C, Heerspink HJL, Pecoits-Filho R, Ricardo AC, Stengel B, Tonelli M, Cheung M, Jadoul M, Winkelmayer WC, Kramer H; Conference Participants. Trends and perspectives for improving quality of chronic kidney disease care: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023 Nov;104(5):888-903. doi: 10.1016/j.kint.2023.05.013. Epub 2023 May 26.

Fletcher RA, Arnott C, Rockenschaub P, Schutte AE, Carpenter L, Vaduganathan M, Agarwal R, Bakris G, Chang TI, Heerspink HJL, Jardine MJ, Mahaffey KW, Neal B, Pollock C, Jun M, Rodgers A, Perkovic V, Neuen BL. Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials. J Am Heart Assoc. 2023 Jul 4;12(13):e028516. doi: 10.1161/JAHA.122.028516. Epub 2023 Jun 22.

Fletcher RA, Jongs N, Chertow GM, McMurray JJV, Arnott C, Jardine MJ, Mahaffey KW, Perkovic V, Rockenschaub P, Rossing P, Correa-Rotter R, Toto RD, Vaduganathan M, Wheeler DC, Heerspink HJL, Neuen BL. Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials. J Am Soc Nephrol. 2023 Dec 1;34(12):1965-1975. doi: 10.1681/ASN.0000000000000248. Epub 2023 Oct 25.

Gao F, Huang Z, Liang J, Kang Y, Ling Y, He Y, Chen J, Hong D, Zhang Z, Xu S, Wang A, Yan X, Liu J, Liu Y, Chen S, Chen J. Association of malnutrition with all-cause and cardiovascular mortality in patients with mild to severe chronic kidney disease undergoing coronary angiography: a large multicenter longitudinal study. Int Urol Nephrol. 2023 Dec;55(12):3225-3236. doi: 10.1007/s11255-023-03566-5. Epub 2023 Apr 27.

Ha JT, Scaria A, Andrade J, Badve SV, Birks P, Bota SE, Campain A, Djurdjev O, Garg AX, Harel Z, Hemmelgarn B, Hockham C, James MT, Jardine MJ, Lam D, Levin A, McArthur E, Ravani P, Shao S, Sood MM, Tan Z, Tangri N, Whitlock R, Gallagher M, Jun M. Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada. Kidney Med. 2023 May 16;5(7):100675. doi: 10.1016/j.xkme.2023.100675.

Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1.

Inker LA, Collier W, Greene T, Miao S, Chaudhari J, Appel GB, Badve SV, Caravaca-Fontán F, Del Vecchio L, Floege J, Goicoechea M, Haaland B, Herrington WG, Imai E, Jafar TH, Lewis JB, Li PKT, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Wetzels JFM, Woodward M, Heerspink HJL; CKD-EPI Clinical Trials Consortium. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med. 2023 Jul;29(7):1867-1876. doi: 10.1038/s41591-023-02418-0. Epub 2023 Jun 17.

Jun M, Scaria A, Andrade J, Badve SV, Birks P, Bota SE, Campain A, Djurdjev O, Garg AX, Ha J, Harel Z, Hemmelgarn B, Hockham C, James MT, Jardine MJ, Levin A, McArthur E, Ravani P, Shao S, Sood MM, Tan Z, Tangri N, Whitlock R, Gallagher M. Kidney function and the comparative effectiveness and safety of direct oral anticoagulants vs. warfarin in adults with atrial fibrillation: a multicenter observational study. Eur Heart J Qual Care Clin Outcomes. 2023 Sep 12;9(6):621-631. doi: 10.1093/ehjqcco/qcac069.

Kang A, Smyth B, Neuen BL, Heerspink HJL, Di Tanna GL, Zhang H, Arnott C, Hockham C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Mahaffey KW, Perkovic V, Jardine MJ. The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials. Diabetes Obes Metab. 2023 Aug;25(8):2151-2162. doi: 10.1111/dom.15091. Epub 2023 May 10.

Koshino A, Oshima M, Arnott C, Fletcher RA, Bakris GL, Jardine M, Mahaffey KW, Perkovic V, Pollock C, Heerspink HJL, Neuen BL. Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Diabetes Obes Metab. 2023 May;25(5):1413-1418. doi: 10.1111/dom.14978. Epub 2023 Feb 6.

Li Q, Huang H, Chen W, Shi S, Lu X, Lai W, Liang G, Wu J, Chen J, Liu J, Chen S, Wang AY, Liu Y. Trends in incidence and mortality of acute kidney disease following coronary angiography in the Chinese population: 2008–2017. Medicine Advances. 2023;1(2):123-132.

Lu X, Li Q, Deng J, Kang Y, Liang G, Deng L, Guo L, Ruan H, Peng Z, Li J, Tan N, Chen J, Liu J, Wang AY, Liu Y. Renal Insufficiency Increases the Combined Risk of Left Ventricular Hypertrophy and Dysfunction in Patients at High Risk of Cardiovascular Diseases. J Clin Med. 2023 Feb 24;12(5):1818. doi: 10.3390/jcm12051818.

Macdougall IC, Meadowcroft AM, Blackorby A, Cizman B, Cobitz AR, Godoy S, Jha V, Johansen KL, McMahon G, Obrador GT, Wong MG, Singh AK. Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D). Am J Nephrol. 2023;54(1-2):1-13. doi: 10.1159/000528696. Epub 2023 Feb 7.

Mehrotra R, Davison SN, Farrington K, Flythe JE, Foo M, Madero M, Morton RL, Tsukamoto Y, Unruh ML, Cheung M, Jadoul M, Winkelmayer WC, Brown EA; Conference Participants. Managing the symptom burden associated with maintenance dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023 Sep;104(3):441-454. doi: 10.1016/j.kint.2023.05.019. Epub 2023 Jun 7.

Mohebi R, Liu Y, Hansen MK, Yavin Y, Sattar N, Pollock CA, Butler J, Jardine M, Masson S, Heerspink HJL, Januzzi JL Jr. Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial. Cardiovasc Diabetol. 2023 Jul 12;22(1):176. doi: 10.1186/s12933-023-01916-2.

Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3.

Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3.

Sun J, Wong MG. Haematuria in immunoglobulin a nephropathy: To be or not to be? Nephrology (Carlton). 2024 Feb;29(2):63-64. doi: 10.1111/nep.14272. Epub 2024 Jan 17.

Talbot B, Cass A, Walker R, Hooi L, Jardine M, Jun M, Rogers K, Sukkar L, Smyth B, Gallagher M. Comparing survival in patients with chronic kidney disease across three countries - Results from the study of heart and renal protection-extended review. Nephrology (Carlton). 2023 Jan;28(1):36-43. doi: 10.1111/nep.14127. Epub 2022 Nov 9.

Talbot B, Davies S, Burman J, Ritchie A, Snelling P, Lynch S, Park Y, Jones B, Garvey V, Jaure A, Jardine M, Perkovic V, Gallagher M, Brandwood A, Kaur N, Knight J. The Point-of-Care Peritoneal Dialysis System Early Evaluation Study (POC-PDEE): A pilot proof-of-principal study of the Ellen Medical Devices Point-of-Care affordable peritoneal dialysis system. Perit Dial Int. 2024 Jan 5:8968608231209850. doi: 10.1177/08968608231209850. Epub ahead of print.

Tran TB, Shah K, Rejuso A, Foote C, Sen S, Thom J, Arnold R. IPOS-R mobility score, utility and uptake: a retrospective clinical audit. Renal Society of Australasia Journal. 2023;19(1).

van der Hoek S, Jongs N, Oshima M, Neuen BL, Stevens J, Perkovic V, Levin A, Mahaffey KW, Pollock C, Greene T, Wheeler DC, Jardine MJ, Heerspink HJL. Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial. Clin J Am Soc Nephrol. 2023 Jun 1;18(6):748-758. doi: 10.2215/CJN.0000000000000161. Epub 2023 Mar 31.

Wang M, Qin M, Wang AY, Zhao JW, Deng F, Han Y, Wang W. Clinical Manifestations and Risk Factors Associated with 14 Deaths following Swarm Wasp Stings in a Chinese Tertiary Grade A General Hospital: A Retrospective Database Analysis Study. J Clin Med. 2023 Sep 6;12(18):5789. doi: 10.3390/jcm12185789. PMID: 37762730; PMCID: PMC10532120.

Wang W, Wu S, Wang AY, Wu T, Luo H, Zhao JW, Chen J, Li Y, Ding H. Thrombomodulin activation driven by LXR agonist attenuates renal injury in diabetic nephropathy. Front Med (Lausanne). 2023 Jan 9;9:916620. doi: 10.3389/fmed.2022.916620.

Wu J, Cai H, Xia J, Zhang T, Yan J, Shao X, Wang AY, Shen J, Mou S. SGLT2i: Therapeutic options or contributing factors of contrast-induced acute kidney injury in the setting of non-diabetes? Pharmacol Res. 2023 Sep;195:106883. doi: 10.1016/j.phrs.2023.106883. Epub 2023 Aug 5.

Yeung J, Dix CHK, Ritchie AG, Kow M, Chen VMY. Tinzaparin for venous thromboembolism in patients with renal impairment: a single-centre, prospective pilot study. Intern Med J. 2023 Jan;53(1):68-73. doi: 10.1111/imj.15010. Epub 2022 Dec 5.

Yi TW, Smyth B, Di Tanna GL, Arnott C, Cardoza K, Kang A, Pollock C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Heerspink HJL, Neal B, Wheeler DC, Cannon CP, Zhang H, Zinman B, Perkovic V, Levin A, Mahaffey KW, Jardine M; CREDENCE Trial Investigators. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. Am J Kidney Dis. 2023 Jul;82(1):84-96.e1. doi: 10.1053/j.ajkd.2022.12.015. Epub 2023 Mar 7.

Young TK, Hockham C, Sukkar L, Kang A, Jun M, Foote C, Baker J, Rogers K, Zoungas S, Cass A, Sullivan D, Jardine MJ. Duration and effectiveness of glucose-lowering regimens in the real-world management of diabetes: Data from the Australian EXTEND45 Linked Cohort Study. Endocrine and Metabolic Science. 2023;12:1-51.

Renal Medicine Research

Selected Grants

Our Publications

2024

Renal Medicine Research

Renal Medicine Research

Our Organisation

Make a Donation

Our Hospitals

Care in our Community

Right to Information

Your feedback

Plans

Publications

Quick Links